Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) w...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/826 |